Imunon Inc (IMNN)vsInsmed Inc (INSM)
IMNN
Imunon Inc
$2.78
-5.44%
HEALTHCARE · Cap: $9.76M
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
Smart Verdict
WallStSmart Research — data-driven comparison
Insmed Inc generates 485038% more annual revenue ($606.42M vs $125,000). IMNN leads profitability with a 0.0% profit margin vs -2.1%. INSM appears more attractively valued with a PEG of 1.09. INSM earns a higher WallStSmart Score of 39/100 (F).
IMNN
Avoid23
out of 100
Grade: F
INSM
Hold39
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
No standout strengths identified
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : IMNN
The strongest argument for IMNN centers on Price/Book.
Bull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bear Case : IMNN
The primary concerns for IMNN are Revenue Growth, EPS Growth, Market Cap.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Key Dynamics to Monitor
IMNN profiles as a value stock while INSM is a turnaround play — different risk/reward profiles.
IMNN carries more volatility with a beta of 2.16 — expect wider price swings.
INSM is growing revenue faster at 1.5% — sustainability is the question.
IMNN generates stronger free cash flow (-4M), providing more financial flexibility.
Bottom Line
INSM scores higher overall (39/100 vs 23/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Imunon Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Imunon Inc. is a clinical-stage biotechnology firm focused on pioneering immune-mediated therapies aimed at combating cancer and infectious diseases. Utilizing its proprietary INFECT platform, the company is dedicated to enhancing immune responses that facilitate the effective eradication of malignancies. With a robust pipeline of therapeutics in various stages of clinical evaluation and strategic collaborations that bolster its research capabilities, Imunon is well-positioned to drive notable advancements in immunotherapy, ultimately transforming patient care and establishing a competitive foothold in the biopharmaceutical sector.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?